A Single- and Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2017
At a glance
- Drugs LY 3002813 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Sponsors Eli Lilly
- 09 Dec 2016 Planned End Date changed from 1 Feb 2019 to 1 Jun 2020.
- 09 Dec 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Jun 2020.
- 09 Sep 2016 Planned End Date changed from 1 Aug 2018 to 1 Feb 2019.